On Jul. 29, 2020, Sanofi and GSK announced an agreement with the UK government for the supply of up to 60 million doses of a COVID-19 vaccine.

The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant technology.